TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subject between the ages of \>=18 and \<=40 years~* Negative urine pregnancy test for all female subjects of childbearing potential prior to test article administration and at the completion of the study.~* All female or male subjects who are biologically capable of having children must agree to abstinence or commit to the use of a reliable method of birth control during for the duration of the study and for 30 days after early discontinuation. 4. Hemoglobin levels \>=12.0 and \<=16.5 g/dL for female subjects and \>=13.0 and \<=18.5 g/dL for male subjects.~* Blood pressure: Systolic blood pressure \>90 and \<160 mm Hg; Diastolic blood pressure \>60 and \<95 mm Hg.~* Body weight \>=45 and \<=120 kg.~* Able to be contacted by telephone during the study period.~Exclusion Criteria:~* Pregnancy or breastfeeding women~* Prior vaccination with a serogroup B meningococcal vaccine.~* A previous anaphylactic or severe vaccine-associated adverse reaction.~* A known hypersensitivity to any study vaccine components.~* A known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids (excluding topical, inhalation and intra-articular corticosteroids).~* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.~* Receipt of any blood products, including gamma globulin, in the period from 6 months before study vaccination through the study conclusion.~* Receipt of an inactivated vaccine within 14 days before study vaccinations and live attenuated vaccine within 28 days before study vaccination. This will apply throughout the study until the last vaccination.~* Any clinically significant chronic disease that, in the investigator's judgment may be worsened by blood draw.~* Received any investigational drug, vaccine or device within the 30-day period before study visit 1 and during the conduct of the study.~* History of culture-proven invasive disease caused by N meningitidis or N gonorrhoea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Treatment With rhIGF-1 in GHIS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Height \<-2SD for age and gender~* IGF-1 \<-2SD for age and gender~* Evidence of GH resistance~Exclusion Criteria:~* closed epiphyses~* prior active malignancy~* major organ disfunction~* treatment with medications that would diminish growth~* clinically significant cardiac abnormalities

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- mecasermin, injections BID of rhIGF-1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Toothpaste to Reduce Plaque and Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The inclusion criteria were as follows:~* Apparently healthy men and women age 19-45 with no history of CVD~* All 12 anterior teeth present (canine to canine in both upper and lower arches)~* English speaking~* Ability to commit to two 30 minute appointments These appointment must be 1 month apart)~Exclusion Criteria:~* • Student, faculty or staff with a clinical role at the University of Illinois College of Dentistry~* Individuals taking aspirin, other non-steroidal anti-inflammatory drugs or statins.~* Women who are pregnant or nursing~* Women taking birth control pills or using any hormone released birth control device~* Women on hormone replacement therapy~* Individuals who have taken antibiotics within two weeks of data collection appointment~* Individuals experiencing xerostomia~* Individuals who have experienced an illness, infection or tissue injury within two weeks of data collection appointment~* Individuals with arthritis, lupus or other chronic inflammatory conditions or syndromes~* Individuals with allergies to dyes or over the counter products~* Individuals who have missing anterior teeth, fixed or removable appliances or visible decay or staining in the anterior region (canine to canine in both upper and lower arches)~* Individuals whom have had a dental prophylaxis within 30 days of the data collection visit~* Individuals who have had a new restoration placed (anywhere in the oral cavity) within 30 days of the data collection visit

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Plaque identifying toothpaste (Type: ACTIVE_COMPARATOR): A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
- Non-plaque identifying toothpaste (Type: ACTIVE_COMPARATOR): A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with rheumatoid arthritis and coexistent coronary artery disease or without CAD who had an inadequate response to disease modifying antirheumatic drugs (DMARDs) and corticosteroids and were going to initiate treatment with interleukin-1 inhibitor.~Exclusion Criteria:~* Familiar hyperlipidemia~* Diabetes mellitus~* Chronic obstructive pulmonary disease or asthma, moderate or severe valvular heart disease, primary cardiomyopathies,malignant tumors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- anakinra (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures~* With singleton pregnancy, at least 12 weeks but not more than 31 weeks pregnant at the time of screening~* Agree not to breastfeed for the duration of the study~* Currently on a stable antiretroviral regimen for ≥ 6 months preceding the screening visit~* Documented plasma HIV-1 ribonucleic acid (RNA) levels of \< 50 copies/mL for ≥ 6 months preceding the screening visit and have HIV-1 RNA \< 50 copies/mL at the screening visit~* Have no documented or suspected resistance to FTC, Tenofovir (TFV), or integrase strand-transfer inhibitors (INSTIs) including, but not limited to, the reverse transcriptase resistance mutations K65R or M184V/I~* Have a normal ultrasound, completed locally prior to the Day 1 visit, with no evidence of any fetal malformation or structural abnormality affecting either fetus or placenta~* Normal maternal alfa-fetoprotein level at the screening visit~Key Exclusion Criteria:~* Have chronic hepatitis B virus (HBV)~* Have active hepatitis C virus (HCV) infection~* An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- B/F/TAF (Type: EXPERIMENTAL): Pregnant women participants will receive fixed dose combination (FDC) tablet of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for up to 38 weeks (from the second or third trimesters of pregnancy, depending on enrollment, through 12 weeks post-partum).
- Neonates (Type: NO_INTERVENTION): Neonates who will be born to women participants in the study will be followed from birth up to 8 weeks of age after obtaining consent from the parent or legal guardian. None of the neonates that participate in the study will be treated with the study drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult outpatients with opioid-induced constipation and chronic non-malignant pain.~* Taking oral, transdermal, intravenous, or subcutaneous opioids.~* Willingness to discontinue all pre-study laxative therapy and use only study permitted rescue laxatives.~Exclusion Criteria~* History of chronic constipation before the initiation of opioid therapy.~* Other GI disorders known to affect bowel transit.~* Women who are pregnant, breast-feeding, or plan to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-70 years, male or female;~2. Subject meets one of the following conditions:~1) Subject with a history of gout has a serum uric acid ≥480μmol/l at screening; 2) Subject with a history of hyperuricemia has a serum uric acid ≥540μmol/l at screening, and requiring long-term uric acid-lowering therapy per the investigator's judgment; 3) Subject with a history of hyperuricemia has a serum uric acid≥480μmol/l at screening, on stable treatment for hypertensive, hyperlipidemia or diabetes for at least 3 month, and requiring long-term uric acid-lowering therapy per the investigator's judgment; 3. 18kg/m2≤ BMI ≤32kg/m2.~Exclusion Criteria:~1. Subject who is pregnant or breastfeeding;~2. Alanine aminotransferase or Aspartate aminotransferase or total bilirubin\>1.5 upper normal limit;~3. Estimated glomerular filtration rate (MDRD formula) ˂60ml/min;~4. HbA1c˃8%;~5. Subject with known hypersensitivity or allergy to SHR4640 or any component of SHR4640;~6. Subject with a history of malignancy;~7. Subject with a history of urolithiasis, or positive findings on ultrasound examination at screen~8. Subject within the last 3months has: myocardial infarction, angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemia attack;~9. Subject has acute gout flares within 2 weeks before randomization;~10. Subject who is taking any other urate-lowering medication (allopurinol, febuxostat, probenecid and benzbromarone) that is indicated within 2 weeks before randomization and can not stop during the study;~11. Subject who is taking more than 100mg once daily or unstable dosage aspirin within 2 weeks before randomization and can not stop during the study;~12. Subject who is taking any diuretic within 2 weeks before randomization and can not stop during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo for 5 weeks
- 2.5mg SHR4640 (Type: EXPERIMENTAL): SHR4640 for 5 weeks
- 5mg SHR4640 (Type: EXPERIMENTAL): SHR4640 for 5 weeks
- 10mg SHR4640 (Type: EXPERIMENTAL): SHR4640 for 5 weeks
- 50mg benzbromarone (Type: ACTIVE_COMPARATOR): Benzbromarone for 5 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community dwelling patients 65 years of age or older diagnosed with Type 2 Diabetes not controlled with diet and exercise~* Patients must have a HbA1c of 7-10% off medication, or as a result of a protocol wash-out from oral anti-hyperglycemic agents by the qualifying visit~Exclusion Criteria:~* Patients with type 1 diabetes~* History of ketoacidosis or requires insulin use~* Alanine aminotransferase / aspartate aminotransferase \> 2.5 X ULN, triglycerides \> 600 mg/dL, creatinine clearance \< 35 mL/min~* Fasting plasma glucose consistently \> 260 mg/dL~* Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): sitagliptin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Age ≥18 years~* Stage I-III breast cancer~* ECOG 0-2~* Received docetaxel-containing chemotherapy~Exclusion Criteria:~* Existed any chronic pain or peripheral neuropathy~* Prior history of gastrointestinal bleeding or ulcer~* Long-term history of receiving oral corticoids, nonsteroid anti-inflammatory drugs (NSAIDs) or anti-histamines~* Allergies to NSAIDs or aspirin~* Blood creatinine level exceeds 1.5 times of the upper limit of normal range

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etoricoxib (Type: EXPERIMENTAL): Prophylactic etoricoxib (60 mg) was administered orally at each course of docetaxel-containing chemotherapy, which started from the day of chemotherapy and was performed once per day for 8 days (day 1-8).
- Control (Type: NO_INTERVENTION): No prophylactic regimen was given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have had dry eye syndromes in single eye or in both eyes (ICD-10 : H04.1). He or she must have both of the conditions below:~  1. Patients who have dry eye symptoms such as itching, ocular foreign body sensation, ocular burning, ocular pain, ocular dryness, blurred vision, sensation of photophobia, ocular redness, sensation of tearing~ 2. Patients whose tear film break-up time is below 10 seconds and Schirmer I test results is below 10mm/5sec.~Exclusion Criteria:~* Patients who have defects of the eyelid or eyelashes~* Acute infection of the eyelid, eyeball or eye accessories~* Stevens-Johnson syndrome~* Vitamin A deficiency~* Eye or accessory defects due to external injuries~* A past history of surgical operation related to the eye in last three months~* Punctual occlusion~* Current usage of contact lenses~* Sequelae of facial palsy,~* Current usage of anti-inflammatory eye drops in the last two weeks~* Pregnancy~* Using history of traditional medicinal treatment such as acupuncture, moxibustion and herbal medicine in the last one month

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Acupuncture (Type: EXPERIMENTAL): None
- Artificial tear drop (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modifying (Phase I) and Evaluating (Phase II) Virtual Reality Job Interview Training for Youth in Transition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 16-26 years old and enrolled in high school or post-high school transition programming;~2. Educational Diagnosis of autism spectrum disorder using the Social Responsivity Scale 2nd Edition28, or a diagnosis of cognitive impairment, emotional disability, educational impairment or other health impairment according to the students Individualized Education Plan (IEP). They may have diagnosis of autism spectrum disorder as indicated in their IEP/school plan, or as indicated by a parent;~3. Fluency in English with at least a 3rd grade reading level (confirmed with the Wide Range Achievement Test);~4. Currently receiving transitional services as specified in IEP or other;~5. Willing to be video-recorded; and~6. Willing and able to provide informed consent.~Exclusion Criteria:~1. Has an uncorrected hearing or visual problem that prevents him or her from using the training.~2. Has a medical illness that compromises their cognition (for example, moderate to severe traumatic brain injury)~Inclusion and exclusion criteria is subject to PI discretion. Some students may still be enrolled after discussion with the teacher if it is determined that they still might be able to participate despite matching exclusion criteria, or not meeting all of the inclusion criteria. These cases will be documented and reported to IRB.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Services as usual + Virtual Reality Job Interview Training (Type: EXPERIMENTAL): In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
- Services as Usual (Type: ACTIVE_COMPARATOR): Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Trauma patients between the ages of 18 and 65 who require 6 or more units of blood product during their initial 12 hours of resuscitation will be considered for enrollment.~Exclusion Criteria:~* Patients with a traumatic brain injury requiring neurosurgical operative intervention or who have neurologic trauma deemed non-survivable will also be excluded.~* Patients with an active coronary syndrome, history of myocardial infarction or coronary artery disease will be excluded.~* Patients with known renal dysfunction requiring dialysis will be excluded.~* Patients who are pregnant will be excluded.~* Patients less than 18 years old will be excluded.~* Patients who have opted out by bracelet identification or by listing themselves on the Non-Participant roster.~* Patients under the jurisdiction of the department of corrections and considered prisoners prior to the initiation of the research intervention will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vasopressin (Type: ACTIVE_COMPARATOR): Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
- Normal Saline (Type: PLACEBO_COMPARATOR): An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete